UNSPSC 51391805: Methoxyphenamine

This classification denotes a beta-adrenergic agonist with the molecular formula C11H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3Z5SRI26Z, chemically known as 2-methoxy-n,alpha-dimethylphenethylamin but generally known as methoxyphenamine, which bears US NIH Compound Identifier 4117. European Medicines Agency schedules Methoxyphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08860MIG.

UNSPSC 51391805 Methoxyphenamine (Commodity) shows minimal relevant recent activity under state and local procurement. The code's nominal scope—a specific pharmaceutical compound—does not align with the recent opportunities tagged to it. Seminole County, Florida's IFB60459723LAS (posted June 30, 2026; response due July 26, 2023) solicits naloxone and drug deactivation systems for community health initiatives with quarterly deliveries, a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) explores direct-to-manufacturer prescription programs and vendor capabilities for pharmacy benefit contracting, not methoxyphenamine procurement specifically. Neither opportunity targets methoxyphenamine as a product line or demonstrates active state and local demand under this code.

The mismatch between the code's pharmaceutical-compound specificity and the broader drug-policy and pharmacy-benefit work tagged to it signals that this Commodity code sees little targeted procurement activity. Issuing bodies engaging with related pharmaceutical and drug-policy work—county health departments and state health agencies—operate under different UNSPSC classifications when procuring specific pharmaceutical products or services. Business development professionals should verify actual customer procurement patterns through primary RFP, RFQ, and IFB channels rather than relying on this code as a reliable procurement signal. The code warrants monitoring if state and local health agencies begin direct procurement of methoxyphenamine for specific therapeutic or emergency-response programs, but current activity does not support active pursuit.